EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

Zoe R Maylin iD, Christopher Smith iD, Adam Classen, Mohammad Asim, Hardev Pandha, Yuzhuo Wang iD

Cells · 03.12.2024 · 13 (23) · 1999

DOI: 10.3390/cells13231999 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 03.12.2024. Verfasst von Zoe R Maylin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Prostate Centre, Department of Urological Sciences, University of British Columbia, Vancouver, BC V6H 3Z6, Canada. Hauptthemen laut MEDLINE: Cell Transdifferentiation, Prostatic Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, the Prostate Cancer Foundation, the Prostate Project, Univar studentship funding, HOX therapeutics Ltd. CIHR (YW)., Medical Research Council, Prostate Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine prostate cancer (NEPC), an aggressive and lethal subtype of prostate cancer (PCa), often arises as a resistance mechanism in patients undergoing hormone therapy for prostate adenocarcinoma. NEPC is associated with a significantly poor prognosis and shorter overall survival compared to conventional prostate adenocarcinoma due to its aggressive nature and limited response to standard of care therapies. This transdifferentiation, or lineage reprogramming, to NEPC is characterised by the loss of androgen receptor (AR) and prostate-specific antigen (PSA) expression, and the upregulation of neuroendocrine (NE) biomarkers such as neuron-specific enolase (NSE), chromogranin-A (CHGA), synaptophysin (SYP), and neural cell adhesion molecule 1 (NCAM1/CD56), which are critical for NEPC diagnosis. The loss of AR expression culminates in resistance to standard of care PCa therapies, such as androgen-deprivation therapy (ADT) which target the AR signalling axis. This review explores the drivers of NE transdifferentiation. Key genetic alterations, including those in the tumour suppressor genes RB1, TP53, and PTEN, and changes in epigenetic regulators, particularly involving EZH2 and cell-fate-determining transcription factors (TFs) such as SOX2, play significant roles in promoting NE transdifferentiation and facilitate the lineage switch from prostate adenocarcinoma to NEPC. The recent identification of several other key novel drivers of NE transdifferentiation, including MYCN, ASCL1, BRN2, ONECUT2, and FOXA2, further elucidates the complex regulatory networks and pathways involved in this process. We suggest that, given the multifactorial nature of NEPC, novel therapeutic strategies that combine multiple modalities are essential to overcome therapeutic resistance and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell TransdifferentiationProstatic NeoplasmsHumansMaleReceptors, Androgen

Stichwörter der Autor:innen

cancerlineage plasticityneuroendocrineprostatetransdifferentiation

Substanzen

Receptors, Androgen

Autor:innen und Institutionen

  • Vancouver Prostate Centre, Department of Urological Sciences, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
  • Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
  • Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7WG, UK.

ORCID-Profile: Zoe R Maylin, Christopher Smith, Yuzhuo Wang

Förderung

  • Medical Research Council, the Prostate Cancer Foundation, the Prostate Project, Univar studentship funding, HOX therapeutics Ltd. CIHR (YW).
  • Medical Research Council
  • Prostate Cancer Foundation
  • Univar Studentship Funding
  • HOX Therapeutics Ltd.
  • CIHR
  • Terry Fox Research Institute

Zitieren

APA

Maylin, Z. R., Smith, C., Classen, A., Asim, M., Pandha, H., & Wang, Y. (2024). Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. Cells, 13(23), 1999. https://doi.org/10.3390/cells13231999

Vancouver

Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. Cells. 2024;13(23):1999. doi:10.3390/cells13231999

BibTeX
@article{Maylin2024,
  author = {Maylin, Zoe R and Smith, Christopher and Classen, Adam and Asim, Mohammad and Pandha, Hardev and Wang, Yuzhuo},
  title = {Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {23},
  pages = {1999},
  doi = {10.3390/cells13231999}
}
Kostenlos starten →